Liver toxicities triggered a partial clinical hold on Merck’s trial studying its BTK inhibitor candidate for multiple sclerosis.
Merck’s BTK Inhibitor Evobrutinib Slapped with Partial Clinical Hold Read More »
ATMA Journey Centers Inc. is pleased to announce it has submitted an N500 3,4-Methylenedioxymethamphetamine (MDMA) phase II Clinical Trial Application (CTA) to Health Canada.
ATMA Submits N500 MDMA Phase II Clinical Trial Application to Health Canada Read More »
La deficiencia de la tirosina hidroxilasa (THD) es una enfermedad genética ultrarrara que afecta a los niños. Esta enfermedad causa una disminución importante de la dopamina —uno de los neurotransmisores más importantes del sistema nervioso central— en el cere …
En el mundo actual, donde todo ocurre a un ritmo vertiginoso, estar conectado es más importante que nunca. Ya sea que trabaje de forma remota, se mantenga en contacto con amigos y familiares o simplemente navegue por la web, necesita un teléfono con impresionantes capacidades …
Merck announced the U.S. FDA has accepted for review a new supplemental Biologics License Application seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
BioVentrix, Inc., a privately held medical device company developing minimally invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process in patients with congestive heart failure, announced the completion of $48.5 million Series A round financing.
BioVentrix® Closes $48.5 Million Series A Financing Read More »
Genentech, a member of the Roche Group, announced that new data for its approved and investigational medicines will be highlighted in 30 abstracts at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting, which will be held from April 23-27 in New Orleans, LA.
BioWorld™ published by Clarivate Plc, a global leader in connecting people and organizations to intelligence they can trust to transform their world, has released a new special series, Radiopharmaceuticals: The next big disrupter.
Imagine la siguiente situación: un niño pequeño pregunta a un robot de compañía, o a un chatbot de internet, o simplemente al asistente de voz de su teléfono móvil, si Papá Noel es real. ¿Qué deberían contestarle estos sist …
En este Short conoceremos un planeta particular donde existen altas temperaturas a pesar de estar lejos de su estrella. …
Mucho calor en un planeta sin ninguna estrella cerca Read More »
